Replies to post #704 on Mast Therapeutics Inc (fka MSTX)

[J-RO]

IN PLAY Feature =>
6:05AM ADVENTRX Pharma announces ANX-514 clinical development plan affirmed by FDA (ANX) 2.32 : Co announces that it has received confirmation from the FDA regarding its proposed 505(b)(2) NewDrug Application regulatory path for ANX-514. The FDA has indicated that data from a single study of approx 28 patients that demonstrates the bioequivalence of ANX-514 and docetaxel is sufficient tosupport filing an NDA.

http://finance.yahoo.com/marketupdate/inplay